Al. Lancet 2009, 373(9665):723?31. Wallentin L, Varenhorst C, James S, Erlinge D, Braun O? Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A: Prasugrel achieves higher and more quickly P2Y12receptor-mediated platelet inhibition than clopidogrel due to extra efficient generation of its active metabolite in aspirin-treated sufferers with coronary artery disease. Eur Heart J 2008, 29(1):21?0. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R and the HORIZONS-AMI Trial Investigators: Bivalirudin during main PCI in acute myocardial infarction. N Engl J Med 2008, 358(21):2218?230. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D: Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: Rapid (Speedy Activity of Platelet Inhibitor Drugs) key PCI study. J Am Coll Cardiol 2013, 61(15):1601?606. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R: Prasugrel versus tirofiban bolus with or without the need of brief post-bolus infusion with or devoid of concomitant prasugrel administration in sufferers with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation by way of Aggrastat By drOpping or shortening Infusion Line in individuals with ST-segment elevation myocardial infarction in comparison with or on major of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012, 5(three):268?77. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML: Thrombolysis in Myocardial Infarction (TIMI) Trial – Phase 1: Haemorrhagic Manifestations and adjustments in plasma fibrinogen and the fibrinolytic system in individuals treated with recombinant tissue plasminogen activator and streptokinase. JACC 1988, 11(1):1?1. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H: Standardized bleeding definitions for cardiovascular clinical trials. Circulation 2011, 123(23):2736?747. Mauri L, Hsieh W-h, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE: Stent thrombosis in randomized clinical trials of drug-eluting stents.199277-80-0 Chemical name N Engl J Med 2007, 356(ten):1020?029.2-Bromo-5-chlorotoluene Chemscene Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Sch ig A, Kastrati A, von Beckerath N: Platelet reactivity immediately after clopidogrel treatment assessed with point-of-care evaluation and early drug-eluting stent thrombosis.PMID:23255394 J Am Coll Cardiol 2009, 53(ten):849?56. Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Mckel M, Caixeta A, Parise H, White H, Stone GW: Impact of switching antithrombin agents for major angioplasty in acute myocardial infarction: the HORIZONS-SWITCH evaluation. J Am Coll Cardiol 2011, 57(23):2309?316. Langrish JP, Fox KAA: Optimal antithrombotic therapy during major percutaneous coronary intervention? Heart 2011, 97(18):1459?460. Koutouzis M, Lagerqvist B, James S, Omerovic E, Matejka G, Grip L, Albertsson P: Unfractionated heparin administration in sufferers treated with bivalirudin through major percutaneous coronary intervention is associated decrease mortality and target lesion thrombosis: a report in the Swedish Coronary Angiography and Angioplasty Regi.